Krystal Biotech Inc (NASDAQ:KRYS) has received an average recommendation of “Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $35.88.
A number of equities research analysts have recently weighed in on the company. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Krystal Biotech in a research note on Monday, August 6th. Cantor Fitzgerald assumed coverage on Krystal Biotech in a research note on Monday, September 10th. They issued an “overweight” rating and a $28.00 price objective for the company. William Blair assumed coverage on Krystal Biotech in a research note on Tuesday, July 10th. They issued an “outperform” rating for the company. Zacks Investment Research raised Krystal Biotech from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Saturday, August 11th. Finally, HC Wainwright assumed coverage on Krystal Biotech in a research note on Monday, September 24th. They issued a “buy” rating and a $32.00 price objective for the company.
In related news, insider Krish S. Krishnan bought 25,000 shares of the stock in a transaction that occurred on Thursday, October 18th. The stock was purchased at an average cost of $20.00 per share, with a total value of $500,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 45.80% of the company’s stock.
Shares of NASDAQ KRYS traded down $0.83 during trading on Tuesday, reaching $22.67. The stock had a trading volume of 138,337 shares, compared to its average volume of 160,072. Krystal Biotech has a fifty-two week low of $8.03 and a fifty-two week high of $24.89.
Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 6th. The company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.12. As a group, research analysts anticipate that Krystal Biotech will post -1.01 EPS for the current year.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
See Also: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.